NFL Biosciences Advances Smoking Cessation Drug into Phase 2 Trial
Event summary
- NFL Biosciences submitted an application for authorization of its Phase 2 TONIC clinical trial evaluating NFL-102 in smoking cessation.
- The multicenter, randomized, double-blind, placebo-controlled study will include 310 smokers recruited from about ten centers in France.
- The adaptive design allows for the gradual identification of the most effective dose during the study.
- The protocol was optimized to reduce total enrollment by nearly 30% compared to the initial design.
The big picture
NFL Biosciences is advancing its botanical drug candidate NFL-102 into Phase 2 trials, targeting a significant unmet need in smoking cessation. The adaptive design of the TONIC study aims to enhance statistical power while reducing participant exposure to less promising doses. This strategic move positions NFL Biosciences to attract future partners and investors as it seeks to provide a natural alternative for smokers looking to quit.
What we're watching
- Regulatory Approval
- Whether the French National Agency for Medicines and Health Products Safety (ANSM) will authorize the TONIC clinical trial as submitted.
- Dose Optimization
- How effectively the adaptive design of the study identifies the most promising dose of NFL-102.
- Clinical Efficacy
- The pace at which initial data from the first 40 patients will confirm the safety and efficacy of NFL-102 in achieving sustained smoking abstinence.
Related topics